^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD48 overexpression

    i
    Other names: CD48, CD48 Molecule, SLAMF2, BLAST, MCD48, HCD48, BCM1, Signaling Lymphocytic Activation Molecule 2, CD48 Antigen (B-Cell Membrane Protein), B-Lymphocyte Activation Marker BLAST-1, Leukocyte Antigen MEM-102, BCM1 Surface Antigen, SLAM Family Member 2, CD48 Antigen, BLAST1, TCT.1, CD48 Molecule, MEM-102
    Entrez ID:
    962
    1year
    2B4 inhibits the apoptosis of natural killer cells through phosphorylated extracellular signal-related kinase/B-cell lymphoma 2 signal pathway. (PubMed, Cytotherapy)
    In this preclinical study, the engagement of the 2B4-CD48 axis can inhibit the apoptosis of NK cells through the p-ERK/BCL2 signal pathway, leading to an improvement in therapeutic efficiency.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD48 (CD48 Molecule) • IL21 (Interleukin 21)
    |
    CD48 overexpression
    1year
    Epigenetic regulation of CD38/48 by KDM6A mediates NK cell response in multiple myeloma (IMW 2023)
    Introduction: Daratumumab (Dara) is a therapeutic antibody against CD38, which triggers both direct and immune-mediated cytotoxicity in multiple myeloma (MM) cells...KDM6A acts to oppose the EZH2/PRC2 complex by demethylating H3K27me3, and we found that Tazemetostat (Taze), an FDA-approved EZH2 inhibitor, increased the expression of CD38 and CD48 at the protein, mRNA, and surface expression levels, especially in KDM6A-KO cells... Taken together, our data reveal that KDM6A assists in Dara targeting by upregulating CD38 and in Dara cytotoxicity by modulating NK activity through CD48 regulation. By imitating its function using an FDA-approved inhibitor, we may overcome Dara resistance and improve patient outcomes in MM.
    IO biomarker
    |
    CD38 (CD38 Molecule) • KDM6A (Lysine Demethylase 6A) • GZMB (Granzyme B) • CD48 (CD48 Molecule)
    |
    CD38 expression • CD48 overexpression
    |
    Darzalex (daratumumab) • Tazverik (tazemetostat)